Critical role of IFN-γ in CFA-mediated protection of NOD mice from diabetes development

International Immunology

Volumn 21, Issue 11, 2009, Pages 1291-1299

  Mori, Yoshiko ^a   Kodaka, Tetsuro ^a   Kato, Takako ^a   Kanagawa, Edith M ^a   Kanagawa, Osami ^a  

^a Institute of Physical and Chemical Research   (Japan)

Author keywords

CFA; Diabetes; IFN ; NOD mice; Regulatory T cells

Indexed keywords

GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL POPULATION; CONTROLLED STUDY; DIABETES MELLITUS; GENETIC SUSCEPTIBILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ADOPTIVE TRANSFER; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; FREUND'S ADJUVANT; INTERFERON-GAMMA; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; RECEPTORS, INTERFERON; T-LYMPHOCYTES, REGULATORY;

EID: 71049173635     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxp097     Document Type: Article

References (59)

1. Wicker, L. S., Todd, J. A. and Peterson, L. B. 1995. Genetic control of autoimmune diabetes in the NOD mouse. Annu. Rev. Immunol. 13:179.
2. Castano, L. and Eisenbarth, G. S. 1990. Type-I diabetes: A chronic autoimmune disease of human, mouse, and rat. Annu. Rev. Immunol. 8:647.
3. Kikutani, H. and Makino, S. 1992. The murine autoimmune diabetes model: NOD and related strains. Adv. Immunol. 51:285.
4. Todd, J. A., Bell, J. I. and McDevitt, H. O. 1987. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 329:599.
5. Hattori, M., Buse, J. B., Jackson, R. A. et al. 1986. The NOD mouse: Recessive diabetogenic gene in the major histocompatibility complex. Science 231:733.
6. Wicker, L. S., Clark, J., Fraser, H. I. et al. 2005. Type 1 diabetes genes and pathways shared by humans and NOD mice. J. Autoimmun. 25(Suppl.):29.
7. Todd, J. A. 1995. Genetic analysis of type 1 diabetes using whole genome approaches. Proc. Natl Acad. Sci. USA 92:8560.
8. Adeghate, E., Schattner, P. and Dunn, E. 2006. An update on the etiology and epidemiology of diabetes mellitus. Ann. NY Acad. Sci. 1084:1.
9. Akerblom, H. K., Vaarala, O., Hyoty, H., Ilonen, J. and Knip, M. 2002. Environmental factors in the etiology of type 1 diabetes. Am. J. Med. Genet. 115:18.
10. Shehadeh, N., Calcinaro, F., Bradley, B. J., Bruchim, I., Vardi, P. and Lafferty, K. J. 1994. Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet 343:706.
11. Cameron, M. J., Arreaza, G. A., Zucker, P. et al. 1997. IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J. Immunol. 159:4686.
12. Rothe, H., Hausmann, A., Casteels, K. et al. 1999. IL-18 inhibits diabetes development in nonobese diabetic mice by counter-regulation of Th1-dependent destructive insulitis. J. Immunol. 163:1230.
13. Formby, B., Jacobs, C., Dubuc, P. and Shao, T. 1992. Exogenous administration of IL-1 alpha inhibits active and adoptive transfer autoimmune diabetes in NOD mice. Autoimmunity 12:21.
14. Ulaeto, D., Lacy, P. E., Kipnis, D. M., Kanagawa, O. and Unanue, E. R. 1992. A T-cell dormant state in the autoimmune process of nonobese diabetic mice treated with complete Freund's adjuvant. Proc. Natl Acad. Sci. USA 89:3927.
15. Sadelain, M. W., Qin, H. Y., Lauzon, J. and Singh, B. 1990. Prevention of type I diabetes in NOD mice by adjuvant immunotherapy. Diabetes 39:583.
16. McInerney, M. F., Pek, S. B. and Thomas, D. W. 1991. Prevention of insulitis and diabetes onset by treatment with complete Freund's adjuvant in NOD mice. Diabetes 40:715.
17. Wang, T., Singh, B., Warnock, G. L. and Rajotte, R. V. 1992. Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy. Diabetes 41:114.
18. Manirarora, J. N., Kosiewicz, M. M., Parnell, S. A. and Alard, P. 2008. APC activation restores functional CD4(+)CD25(+) regulatory T cells in NOD mice that can prevent diabetes development. PLoS ONE 3:e3739.
19. Qin, H. Y., Sadelain, M. W., Hitchon, C., Lauzon, J. and Singh, B. 1993. Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice. J. Immunol. 150:2072.
20. Serreze, D. V., Chapman, H. D., Post, C. M., Johnson, E. A., Suarez-Pinzon, W. L. and Rabinovitch, A. 2001. Th1 to Th2 cytokine shifts in nonobese diabetic mice: Sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation. J. Immunol. 166:1352.
21. Serreze, D. V., Post, C. M., Chapman, H. D., Johnson, E. A., Lu, B. and Rothman, P. B. 2000. Interferon-gamma receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice. Diabetes 49:2007.
22. Mori, Y., Kato, T., Kodaka, T., Kanagawa, E. M., Hori, S. and Kanagawa, O. 2008. Protection of IFN-gamma signaling-deficient NOD mice from diabetes by cyclophosphamide. Int. Immunol. 20:1231.
23. Sarmiento, M., Loken, M. R. and Fitch, F. W. 1981. Structural differences in cell surface T25 polypeptides from thymocytes and cloned T cells. Hybridoma 1:13.
24. Gotoh, M., Maki, T., Kiyoizumi, T., Satomi, S. and Monaco, A. P. 1985. An improved method for isolation of mouse pancreatic islets. Transplantation 40:437.
25. Kanagawa, O., Militech, A. and Vaupel, B. A. 2002. Regulation of diabetes development by regulatory T cells in pancreatic islet antigen-specific TCR transgenic nonobese diabetic mice. J. Immunol. 168:6159.
26. Judkowski, V., Pinilla, C., Schroder, K., Tucker, L., Sarvetnick, N. and Wilson, D. B. 2001. Identification of MHC class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2.5 nonobese diabetic mice. J. Immunol. 166:908.
27. Lee, I. F., Qin, H., Trudeau, J., Dutz, J. and Tan, R. 2004. Regulation of autoimmune diabetes by complete Freund's adjuvant is mediated by NK cells. J. Immunol. 172:937.
28. Komiyama, Y., Nakae, S., Matsuki, T. et al. 2006. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177:566.
29. Matthys, P., Vermeire, K., Heremans, H. and Billiau, A. 2000. The protective effect of IFN-gamma in experimental autoimmune diseases: A central role of mycobacterial adjuvant-induced myelopoiesis. J. Leukoc. Biol. 68:447.
30. Rosloniec, E. F., Latham, K. and Guedez, Y. B. 2002. Paradoxical roles of IFN-gamma in models of Th1-mediated autoimmunity. Arthritis. Res. 4:333.
31. Skurkovich, S. and Skurkovich, B. 2005. Anticytokine therapy, especially anti-interferon-gamma, as a pathogenetic treatment in TH-1 autoimmune diseases. Ann. NY Acad. Sci. 1051:684.
32. Ferber, I. A., Brocke, S., Taylor-Edwards, C. et al. 1996. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. 156:5.
33. Krakowski, M. and Owens, T. 1996. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur. J. Immunol. 26:1641.
34. Manoury-Schwartz, B., Chiocchia, G., Bessis, N. et al. 1997. High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J. Immunol. 158:5501.
35. Vermeire, K., Heremans, H., Vandeputte, M., Huang, S., Billiau, A. and Matthys, P. 1997. Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J. Immunol. 158:5507.
36. Ring, G. H., Dai, Z., Saleem, S., Baddoura, F. K. and Lakkis, F. G. 1999. Increased susceptibility to immunologically mediated glomerulonephritis in IFN-gamma-deficient mice. J. Immunol. 163:2243.
37. Calderon, B., Suri, A., Pan, X. O., Mills, J. C. and Unanue, E. R. 2008. IFN-gamma-dependent regulatory circuits in immune inflammation highlighted in diabetes. J. Immunol. 181:6964.
38. Kanagawa, O., Xu, G., Tevaarwerk, A. and Vaupel, B. A. 2000. Protection of nonobese diabetic mice from diabetes by gene(s) closely linked to IFN-gamma receptor loci. J. Immunol. 164:3919.
39. Wang, B., Andre, I., Gonzalez, A. et al. 1997. Interferon-gamma impacts at multiple points during the progression of autoimmune diabetes. Proc. Natl Acad. Sci. USA 94:13844.
40. Koike, T., Itoh, Y., Ishii, T. et al. 1987. Preventive effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice. Diabetes 36:539.
41. Bendelac, A., Carnaud, C., Boitard, C. and Bach, J. F. 1987. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells. J. Exp. Med. 166:823.
42. Wang, Y., Pontesilli, O., Gill, R. G., La Rosa, F. G. and Lafferty, K. J. 1991. The role of CD4+ and CD8+ T cells in the destruction of islet grafts by spontaneously diabetic mice. Proc. Natl Acad. Sci. USA 88:527.
43. Nichols, J., Jones, K., Phillips, J. M. et al. 2009. Validated germline-competent embryonic stem cell lines from nonobese diabetic mice. Nat. Med. 15:814.
44. Hanna, J., Markoulaki, S., Mitalipova, M. et al. 2009. Metastable pluripotent states in NOD-mouse-derived ESCs. Cell Stem Cell 4:513.
45. Park, H., Li, Z., Yang, X. O. et al. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6:1133.
46. Hofstetter, H. H., Ibrahim, S. M., Koczan, D. et al. 2005. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol. 237:123.
47. Jain, R., Tartar, D. M., Gregg, R. K. et al. 2008. Innocuous IFNgamma induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production. J. Exp. Med. 205:207.
48. Cain, J. A., Smith, J. A., Ondr, J. K., Wang, B. and Katz, J. D. 2006. NKT cells and IFN-gamma establish the regulatory environment for the control of diabetogenic T cells in the nonobese diabetic mouse. J. Immunol. 176:1645.
49. Mellor, A. L. and Munn, D. H. 2004. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4:762.
50. Munn, D. H., Zhou, M., Attwood, J. T. et al. 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191.
51. Torgerson, T. R. 2006. Regulatory T cells in human autoimmune diseases. Springer Semin. Immunopathol. 28:63.
52. Bluestone, J. A. and Tang, Q. 2005. How do CD4+CD25+ regulatory T cells control autoimmunity? Curr. Opin. Immunol. 17:638.
53. Tarbell, K. V., Petit, L., Zuo, X. et al. 2007. Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J. Exp. Med. 204:191.
54. Salomon, B., Lenschow, D. J., Rhee, L. et al. 2000. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12:431.
55. Brode, S., Raine, T., Zaccone, P. and Cooke, A. 2006. Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 177:6603.
56. Tang, Q., Henriksen, K. J., Bi, M. et al. 2004. In vitro expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 199:1455.
57. Kelchtermans, H., De Klerck, B., Mitera, T. et al. 2005. Defective CD4+CD25+ regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-gamma. Arthritis Res. Ther. 7:R402.
58. Wang, Z., Hong, J., Sun, W. et al. 2006. Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ T cells to CD4+ Tregs. J. Clin. Invest. 116:2434.
59. Willenborg, D. O., Fordham, S., Bernard, C. C., Cowden, W. B. and Ramshaw, I. A. 1996. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J. Immunol. 157:3223.